Interventional device developer Boston Scientific released results from its Taxus Woman study, which found that paclitaxel-eluting stents have similar clinical outcomes in women and men, despite the higher risk profile in female patients.

Results of the gender-specific analysis assessing the efficacy data of the Taxus paclitaxel-eluting coronary stent in women undergoing coronary revascularization were released at the European Society of Cardiology Congress in Vienna, Austria, this week.

The Taxus Woman study analyzed pooled results of women enrolled in trials evaluating the performance of the Taxus stent compared with a bare-metal stent control in patients with coronary artery disease. The women’s results were compared with the corresponding endpoints in men.

According to the Natick, Mass.-based Boston Scientific, there were no other significant differences in baseline demographics, and lesion or procedural characteristics between the Taxus and bare-metal stent groups in both genders.